Abstract | OBJECTIVE: METHODS: The authors recruited from their HIV metabolic clinic 55 adult patients with anthropomorphic changes consistent with HLS together with hypertriglyceridemia. The patients had no prior history of taking lipid-lowering medications and were free of liver and renal disease. They were on various highly active antiretroviral therapy regimens, and these regimens were not altered during the course of the study. Fenofibrate was started at 54 mg a day and the dose increased every 2 weeks to a maximum of 162 mg/day. Fasting lipid concentrations were measured at baseline and 6 months after the intervention. RESULTS: At baseline, the fasting plasma concentrations of total cholesterol, triglyceride, and high-density lipoprotein ( HDL) cholesterol were 259 +/- 11, 886 +/- 172, and 35.7 +/- 2.3 (mean +/- SEM) mg/dL, respectively. After 6 months of fenofibrate treatment, the fasting plasma concentrations were as follows: total cholesterol, 243 +/- 13; triglycerides, 552 +/- 104, and HDL cholesterol, 35.7 +/- 1.8 mg/dL. The decrease in fasting plasma triglyceride concentration was statistically significant (P < 0.05). Fenofibrate was well tolerated, and no subjects dropped out of the study. CONCLUSION:
|
Authors | Archana Rao, Susana D'Amico, Ashok Balasubramanyam, Mario Maldonado |
Journal | The American journal of the medical sciences
(Am J Med Sci)
Vol. 327
Issue 6
Pg. 315-8
(Jun 2004)
ISSN: 0002-9629 [Print] United States |
PMID | 15201643
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
|
Topics |
- Adult
- Female
- Fenofibrate
(therapeutic use)
- HIV-Associated Lipodystrophy Syndrome
(blood, complications, drug therapy)
- Humans
- Hypertriglyceridemia
(blood, complications, drug therapy)
- Male
- Middle Aged
|